Press Releases
KEFEA: New medicine being victimised
Pharmaceutical companies say they are trapped because they cannot delete products from the price list There will be problems in the unimpeded distribution of medicines in the Cyprus market, particularly the availability of new, innovative treatments following the...
KEFEA: In danger of medicinal products being withdrawn
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is concerned about the Minister of Health’s decision to proceed with a further 8.5% horizontal price cut on private sector medicines. This latest, one-sided measure may create problems...
An NHS with free choice of pharmaceuticals
Interview with KEFEA President, Kyriakos Mikellis, published in Politis newspaper Read the interview here 20150222KEFEA President interview
Potential for investment in the pharmaceutical industry
Join initiatives by CIPA – KEFEA The potential to attract investments in the pharmaceutical industry and develop joint initiatives to improve the investment climate were discussed during a meeting between the Cyprus Investment Promotion Agency (CIPA) and the Cyprus...
EFPIA Director General in Cyprus
He will discuss the NHS with the Finance and Health Ministers The implementation of the National Health System (NHS), as well as Cypriot patients’ access to innovative medicines, will be discussed during separate meetings between the Director General of the European...
KEFEA calls on pharmaceutical companies to adopt the Code of Conduct
Pharmaceutical companies will disclose expenses covered for healthcare professionals with the aim of boosting transparency The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) takes press coverage on the World Health Organisation’s (WHO)...
Kyriakos Mikellis is the new KEFEA President
NHS and patients’ access to innovative medicines of top priority Kyriakos Mikellis, Cyprus Business Manger at Pfizer, has been elected as the new President of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) for the next two years....
Responsible Transparency Pharmaceutical companies will disclose transfers of value to healthcare professionals with the aim of increasing transparency
Pharmaceutical companies will disclose transfers of value to healthcare professionals, as part of a Europe-level initiative to apply a stricter self-regulatory framework in the sector and increase transparency. Details on the provisions of the revised “Code of Conduct...
Unacceptable to exclude medicines from the NHS.
KEFEA meeting with the Troika The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) greatly concerned over media reports which claim that only one medicine will be available for every disease following the implementation of the National...
Distorted picture on medicine prices. KEFEA is calling on the Auditor General to back up her claims of being threatened.
Constant references to “expensive” medicines and wrongful comparisons between the private sector prices in Cyprus and prices of other countries with comprehensive health systems, paint a distorted picture of medicine prices in Cyprus. The Cyprus Association of...